Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wils

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
The Netherlands Journal of Medicine|February 1, 1987
Haemolytic-uraemic syndrome associated with mitomycin-C treatmentJ Wils, W Grave, P J van Breda Vriesman
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Phase II study of high-dose epirubicin in non-small cell lung cancerJ Wils, I Utama, L Sala, et al.
Drugs|January 1, 1993
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG)J Wils, R C Coombes, M Marty, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancerH O Klein, J Wils, H Bleiberg, et al.
Cancer Investigation|January 1, 1993
Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The NetherlandsJ Stoot, J Wils, H von Geuns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1987
An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancerA Lacave, J Wils, H Bleiberg, et al.
British Journal of Urology|December 1, 1992
Phase II study of epirubicin in advanced hormone-resistant prostatic carcinomaK P Delaere, H Leliefeld, F Peulen, et al.
European Journal of Cancer & Clinical Oncology|February 1, 1985
Phase II study of epirubicin in advanced adenocarcinoma of the pancreasJ Wils, H Bleiberg, G Blijham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1991
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanomaF Calabresi, M Aapro, D Becquart, et al.
Analytical Biochemistry|January 30, 2002
Characterization of tetanus toxin, neat and in culture supernatant, by electrospray mass spectrometryBen L M van Baar, Albert G Hulst, Beverley Roberts, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
The Netherlands Journal of Medicine|February 1, 1987
Haemolytic-uraemic syndrome associated with mitomycin-C treatmentJ Wils, W Grave, P J van Breda Vriesman
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Phase II study of high-dose epirubicin in non-small cell lung cancerJ Wils, I Utama, L Sala, et al.
Drugs|January 1, 1993
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG)J Wils, R C Coombes, M Marty, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
An EORTC gastrointestinal (GI) group randomized evaluation of the toxicity of sequential high dose methotrexate and 5-fluorouracil combined with adriamycin (FAMTX) vs 5-fluorouracil, adriamycin and mitomycin (FAM) in advanced gastric cancerH O Klein, J Wils, H Bleiberg, et al.
Cancer Investigation|January 1, 1993
Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The NetherlandsJ Stoot, J Wils, H von Geuns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1987
An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancerA Lacave, J Wils, H Bleiberg, et al.
British Journal of Urology|December 1, 1992
Phase II study of epirubicin in advanced hormone-resistant prostatic carcinomaK P Delaere, H Leliefeld, F Peulen, et al.
European Journal of Cancer & Clinical Oncology|February 1, 1985
Phase II study of epirubicin in advanced adenocarcinoma of the pancreasJ Wils, H Bleiberg, G Blijham, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 1991
Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanomaF Calabresi, M Aapro, D Becquart, et al.
Analytical Biochemistry|January 30, 2002
Characterization of tetanus toxin, neat and in culture supernatant, by electrospray mass spectrometryBen L M van Baar, Albert G Hulst, Beverley Roberts, et al.
Pageof 12